Zynerba Pharma Cash Flow - Quarterly (NASDAQ:ZYNE)

Add to My Stocks
$9.14 $0.17 (1.83%) ZYNE stock closing price Mar 21, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like Zynerba Pharma needs to disclose. This statement shows details about the cash generated and spent during a particular quarter, while the other two statements give details about Zynerba Pharma profits and Zynerba Pharma debt. Zynerba Pharma stock analysis shows negative net income cash flow of $-23.89M till 2017 Q3. This statement is important because profits alone cannot pay employees, or bills. Cash is required. Zynerba Pharma saw a outflow of $-0.09M from investing activities till 2017 Q3.

View and download details of Zynerba Pharma cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow---------
Net Increase (Decrease) in Assets Liabilities--2.32M-1.59M-0.49M-0.87M-0.44M-1.17M1.13M-0.33M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net4.26M2.54M1.18M3.36M2.38M1.57M-1.6M-
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.09M-0.07M-0.06M-0.1M-0.08M-0.02M-0.02M-0.21M-0.17M
Acquisition Disposition of Subsidiaires---------
Increase (Decrease) in Investments---------
Other Cash Inflow (Outflow) from Investment Activities---------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares54.68M54.68M54.24M10M5.28M--42.18M42.24M
Issuance (Repayment) of Debt Securities---------
Increase (Decrease) in Bank & Other Borrowings---------
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities-0.17M-0.06M-------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash---------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year41.51M9.33M-------
Cash & Equivalents at Year End66.25M70.17M77.49M30.96M31.78M32.13M36.8M41.51M44.8M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our Pfizer financial analysis

Zynerba Pharma stock price history provides insight into historical stock price fluctuations, and Zynerba Pharma stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Zynerba Pharma had a Net Change in Cash and Cash Equivalents of $35.28M in the latest quarter 2017 Q3. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Zynerba Pharma stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-19.12M for ZYNE.
  • Cash Flow from investment activities: Zynerba Pharma used $-0.09M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Zynerba Pharma earned $54.5M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Zynerba Pharma Cash Flow

FCF margin

Quarterly Cash Flow Statements For Zynerba Pharmaceuticals Inc Peers

Aquinox Pharma cash flow, Marinus Pharma cash flow, Nemus Bioscience cash flow, Pfizer cash flow, SOL GEL TECH cash flow